Research
Hormonal
Luseogliflozin (an SGLT2 inhibitor) significantly reduces epicardial fat volume (EFV) in patients with type 2 diabetes over a 12-week period.
For patients with type 2 diabetes and high BMI, Luseogliflozin can reduce dangerous fat around the heart (epicardial fat) within 3 months. However, it may also reduce muscle mass, so combining this medication with resistance training is recommended to preserve strength.
ModerateSupportsMEDIUM confidence
Luseogliflozin treatment significantly reduced EFV at 12 weeks [117 (96–136) to 111 (88–134), p = 0.048].
Why this rating
Single-arm pilot study with a small sample size (n=19) and short duration (12 weeks), lacking a control group.
Source
Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
Ryotaro Bouchi et al. · Cardiovascular Diabetology · 2017
DOI 10.1186/s12933-017-0516-8
clinical_trial · n=19Cited 172×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →